Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New GSK-3beta inhibitors revealed in Bayer patent

Oct. 10, 2008

Recent patents describe new agents for diabetes and associated disorders

Oct. 9, 2008

Taisho discontinues development of TS-033

Oct. 8, 2008

Mecasermin rinfabate raises IGF-I levels in preterm infants

Oct. 8, 2008

New therapeutic agents for iron-related disorders disclosed in recent Xenon patent

Oct. 8, 2008

Novel pharmacological chaperones identified as promising agents to treat phenylketonuria

Oct. 7, 2008

Unigene initiates phase I study for oral PTH

Oct. 7, 2008

PDC Biotech reports progress on preclinical program for PDC-31

Oct. 7, 2008

Recent Wyeth patent reports novel bazedoxifene prodrugs

Oct. 7, 2008

New agents for diabetic nephropathy disclosed in recent Kowa patent

Oct. 7, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...